Last reviewed · How we verify

Hydroxyethyl Starch

Hospital de Cruces · FDA-approved active Small molecule Quality 5/100

Hydroxyethyl Starch is a Small molecule drug developed by Hospital de Cruces. It is currently FDA-approved. Also known as: Hemoes, Colloid, HES, HES 130/0.4.

At a glance

Generic nameHydroxyethyl Starch
Also known asHemoes, Colloid, HES, HES 130/0.4, Voluven
SponsorHospital de Cruces
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hydroxyethyl Starch

What is Hydroxyethyl Starch?

Hydroxyethyl Starch is a Small molecule drug developed by Hospital de Cruces.

Who makes Hydroxyethyl Starch?

Hydroxyethyl Starch is developed and marketed by Hospital de Cruces (see full Hospital de Cruces pipeline at /company/hospital-de-cruces).

Is Hydroxyethyl Starch also known as anything else?

Hydroxyethyl Starch is also known as Hemoes, Colloid, HES, HES 130/0.4, Voluven.

What development phase is Hydroxyethyl Starch in?

Hydroxyethyl Starch is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing